Search

The article reports on new data comparing the efficacy of three therapies for relapsing multiple sclerosis: diroximel fumarate (DRF), ozanimod (OZA), and interferon beta-1a (IFN). Topics discussed include comparisons of relapse rates, disability progression, and radiological outcomes among the treatments, with DRF generally showing more favorable results compared to IFN and OZA in certain areas.

A recent study conducted by Biogen Inc. evaluated the safety, tolerability, and efficacy of diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis (MS). The study used a composite efficacy endpoint called No Evidence of Disease Activity (NEDA-3), which includes criteria such as no relapse, no disability progression, and no new lesions. The results showed that approximately half of the DRF-treated patients achieved NEDA-3 at week 96 after re-baselining, compared to 36.5% of patients who were not re-baselined. Re-baselining may be a useful approach to assess the efficacy of disease-modifying therapies for MS. [Extracted from the article]

A study conducted by Biogen investigated the potential impact of differences in aggregates on the clinical immunogenicity of biosimilars and their reference products. The study found that there were limited differences in the content of high molecular weight species (HMWs) between marketed biosimilars and reference monoclonal antibodies (mAbs). These differences were not associated with differences in reported immunogenicity, as measured by the incidence of antidrug-antibodies (ADAs) and neutralizing ADAs in comparative clinical studies. The study suggests that HMWs may not have a significant impact on the immunogenicity of biosimilars. [Extracted from the article]